Development of targeted medical care (simultaneous diagnostic imaging and therapy) for pathogenic angiogenesis using fibrinolytic metabolites

通过人脐静脉内皮细胞的细胞抑制活性试验和血管生成成像分析，我们证实了β2-糖蛋白I(B2GPI)的DI具有剂量和时间依赖性的细胞抑制和抗血管生成活性。制备了64铜标记的DI和64铜标记的B2GPI，并用于荷瘤小鼠的PET/CT显像。DI显示肿瘤/血液比值较高。制备了64Cu标记和B2GPI结合的脂质体，作为Theranostics(同时诊断成像和治疗)技术的实验模型。

By the cytostatic activity test and angiogenesis imaging analysis with human umbilical vein endothelial cells, we confirmed that DI of beta2-glycoprotein I (B2GPI) revealed dose- and time-dependent cytostatic and anti-angiogenesis activity. 64Cu-labeled DI and 64Cu-labeled B2GPI were prepared and used for PET/CT imaging of tumor-bearing mice. DI showed high tumor/blood ratio. 64Cu-labeled and B2GPI-bound liposomes were prepared as an experimental model of the Theranostics (simultaneous diagnostic imaging and therapy) technology.